	US 12,486,521 B2
	Platform for expressing protein of interest in liver
Seokjoong Kim, Seoul (KR); Dong Woo Song, Seoul (KR); Kyu Jun Lee, Seoul (KR); Jung-Min Lee, Gyeongsangbuk-do (KR); and Un-Gi Kim, Seoul (KR)
Assigned to TOOLGEN INCORPORATED, Seoul (KR)
Filed by TOOLGEN INCORPORATED, Seoul (KR)
Filed on Apr. 26, 2023, as Appl. No. 18/139,481.
Application 18/139,481 is a division of application No. 16/623,017, granted, now 11,667,934, previously published as PCT/KR2018/006803, filed on Jun. 15, 2018.
Claims priority of provisional application 62/662,907, filed on Apr. 26, 2018.
Claims priority of provisional application 62/520,103, filed on Jun. 15, 2017.
Prior Publication US 2023/0287461 A1, Sep. 14, 2023
Int. Cl. C12N 15/90 (2006.01); A61K 38/17 (2006.01); A61K 48/00 (2006.01); A61P 7/04 (2006.01); C07K 14/775 (2006.01); C12N 9/22 (2006.01); C12N 9/64 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01)

CPC C12N 15/907 (2013.01) [C12N 9/22 (2013.01); C12N 9/644 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01)]

13 Claims

1. An engineered hepatocyte, comprising:

an engineered genome comprising a transgene, wherein the transgene is located within a region of intron 1 of APOC3 gene which is a highly expressed and secretory gene of the engineered genome,

wherein the transgene is inserted into a site which is present within one or mor e sequences selected from SEQ ID NOs: 154-164, 169-182 and its complementary sequence of wild-type APOC3 gene, and

wherein the transgene is expressed at higher levels compared to before insertion, or before the transgene is newly expressed in hepatocyte.